Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.

In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Subroto Chatterjee, Nezar Alsaeedi, Jennifer Hou, Veera Venkata Ratnam Bandaru, Lan Wu, Marc K Halushka, Roberto Pili, Georges Ndikuyeze, Norman J Haughey
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/57d8c0665a9c4073b4e5fa2fe80c1ac4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57d8c0665a9c4073b4e5fa2fe80c1ac4
record_format	dspace
spelling	oai:doaj.org-article:57d8c0665a9c4073b4e5fa2fe80c1ac42021-11-18T07:46:10ZUse of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.1932-620310.1371/journal.pone.0063726https://doaj.org/article/57d8c0665a9c4073b4e5fa2fe80c1ac42013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23671696/?tool=EBIhttps://doaj.org/toc/1932-6203In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer.Subroto ChatterjeeNezar AlsaeediJennifer HouVeera Venkata Ratnam BandaruLan WuMarc K HalushkaRoberto PiliGeorges NdikuyezeNorman J HaugheyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e63726 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Subroto Chatterjee Nezar Alsaeedi Jennifer Hou Veera Venkata Ratnam Bandaru Lan Wu Marc K Halushka Roberto Pili Georges Ndikuyeze Norman J Haughey Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
description	In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer.
format	article
author	Subroto Chatterjee Nezar Alsaeedi Jennifer Hou Veera Venkata Ratnam Bandaru Lan Wu Marc K Halushka Roberto Pili Georges Ndikuyeze Norman J Haughey
author_facet	Subroto Chatterjee Nezar Alsaeedi Jennifer Hou Veera Venkata Ratnam Bandaru Lan Wu Marc K Halushka Roberto Pili Georges Ndikuyeze Norman J Haughey
author_sort	Subroto Chatterjee
title	Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
title_short	Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
title_full	Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
title_fullStr	Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
title_full_unstemmed	Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
title_sort	use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/57d8c0665a9c4073b4e5fa2fe80c1ac4
work_keys_str_mv	AT subrotochatterjee useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT nezaralsaeedi useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT jenniferhou useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT veeravenkataratnambandaru useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT lanwu useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT marckhalushka useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT robertopili useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT georgesndikuyeze useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT normanjhaughey useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel
_version_	1718422970775371776

Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.

Ejemplares similares